Similar to outcome of platinum‐based chemotherapy, several clinical trials have demonstrated that the local failure rate in stage IV NSCLC with EGFR‐M or ALK‐P treated with targeted therapy alone is greater than 80%.18, 19. The gene discussed is ALK; the disease is non-small cell lung carcinoma.